Søren Løntoft Hansen, analyst at Sydbank, believes that the share increase is due to Wegovy sales in the US market.
In December last year, Novo Nordisk became the first to offer a GLP-1 weight-loss drug in tablet form for the US market.
The launch of the pill has exceeded expectations, says Søren Løntoft Hansen.
The US competitor Eli Lilly has also launched a variant, but it was only approved in April this year.
Despite the rise, the stock is still down just over 7 percent since the start of the year.
